시장보고서
상품코드
1957892

종양 침윤 림프구(TIL) 시장 보고서(2026년)

Tumor Infiltrating Lymphocytes Global Market Report 2026

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

종양 침윤 림프구(TIL) 시장 규모는 최근 급성장하고 있습니다. 2025년 120억 5,000만 달러에서 2026년에는 137억 5,000만 달러에 이르고, CAGR 14.2%의 성장이 전망되고 있습니다. 지난 몇 년간의 성장은 암 발병률 증가, 면역치료 연구의 발전, 맞춤형 의료에 대한 인식 증가, 입양세포치료의 초기 단계의 성공, 연구기관과 생명공학 기업 간의 협력 등에 기인하는 것으로 보입니다.

종양 침윤 림프구(TIL) 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 232억 5,000만 달러에 이르고, CAGR은 14.0%를 나타낼 전망입니다. 예측 기간 동안의 성장은 종양 침윤성 림프구 치료의 채택 확대, cGMP 준수 제조 시설의 확대, 세포 치료 프로세스 최적화를 위한 AI 통합, 제약회사와 바이오테크 기업 간의 전략적 제휴 증가, 새로운 T 세포 치료제의 규제 승인 등에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 개인 맞춤형 세포치료제 개발, 체외 T세포 증식 기술, 면역요법 병용 접근법, 종양 미세환경 조절, 첨단 세포 보존 및 동결보존 기술 등을 들 수 있습니다.

암 환자 증가에 따라 종양침윤림프구(TIL) 시장의 성장이 촉진될 것으로 예측됩니다. 암은 체내 세포가 통제할 수 없을 정도로 증식하고 다른 부위로 전이되어 발생하며, 치명적인 결과를 포함한 다양한 건강 문제를 일으킵니다. 종양침윤림프구는 암세포를 감지하고 파괴하는 능력을 가진 면역세포입니다. 이 림프구는 환자의 종양에서 채취하여 실험실에서 증식시킨 후 환자에게 다시 투여하여 면역체계가 암과 싸우는 것을 돕습니다. 예를 들어, 2024년 8월 호주 보건 복지 연구소가 발표한 예측에 따르면, 2034년까지 호주에서 약 20만 9,000건의 신규 암 진단이 발생할 것으로 예상되며, 이는 2024년 예측치인 16만 9,000건에서 크게 증가한 수치입니다. 이 증가는 인구 증가와 암 발생률 증가를 모두 반영하고 있습니다. 또한, 2024년에는 국내 사망 원인 중 약 10건 중 3건이 암으로 인한 사망이 발생할 것으로 예측됩니다. 그 결과, 암 환자 증가가 TIL 치료제 수요를 견인할 것으로 예측됩니다.

종양침윤림프구 시장의 기업들은 유전자 편집을 포함한 혁신적인 치료법 개발을 위해 전략적 제휴를 적극적으로 추진하고 있습니다. 전략적 제휴를 통해 양사는 서로의 강점과 자원을 활용하여 상호 성공을 실현할 수 있습니다. 예를 들어, 2023년 2월, 모델나는 라이프에디트 테라퓨틱스(Life Edit Therapeutics)와 제휴하여 새로운 생체 내 유전자 편집 치료법 개발에 박차를 가하고 있습니다. 이번 협력을 통해 모델나의 mRNA 기술과 라이프에디트의 유전체 편집 플랫폼이 융합되어 암 및 유전성 질환에 대한 보다 효과적인 치료법 개발을 목표로 하고 있습니다.

자주 묻는 질문

  • 종양 침윤 림프구(TIL) 시장 규모는 어떻게 변화하고 있나요?
  • 종양 침윤 림프구(TIL) 시장의 성장은 어떤 요인에 기인하나요?
  • 종양 침윤 림프구(TIL) 치료의 작용 원리는 무엇인가요?
  • 종양 침윤 림프구(TIL) 시장의 주요 동향은 무엇인가요?
  • 종양 침윤 림프구(TIL) 시장에서 기업들은 어떤 전략을 추진하고 있나요?

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

LSH 26.03.17

Tumor-infiltrating lymphocytes (TILs) are immune cells capable of identifying and eliminating cancer cells after they enter a tumor through the bloodstream. These cells are extracted from the patient's tumor, expanded in large quantities in a laboratory, and then reintroduced into the patient to help their immune system target and destroy cancer cells.

The key types of tumor-infiltrating lymphocytes include CD3, CD8, CD16, CD56, CD4, CD57, CD169, CD68, and FOXP3. CD3, also known as the T3 complex, is a multimeric protein complex that plays a crucial role in the activation of T-cells. Tumor-infiltrating lymphocytes consist of various components, including T-cells, B-cells, and natural killer (NK) cells. These immune cells are used in the treatment of various cancers, such as melanoma, cervical cancer, ovarian cancer, and more. The primary end-users of TIL therapy include hospitals, cancer research centers, and clinics.

Tariffs have impacted the tumor infiltrating lymphocytes market by increasing the cost of importing specialized lab equipment, cell culture reagents, and bioreactors, particularly affecting North America and Europe, which rely on global suppliers. The high-cost segments such as ex vivo T-cell expansion and advanced cryopreservation are most affected. While tariffs may slow adoption in price-sensitive regions, they also encourage local manufacturing and innovation in TIL processing technologies, potentially strengthening domestic capabilities.

The tumor infiltrating lymphocytes market research report is one of a series of new reports from The Business Research Company that provides tumor infiltrating lymphocytes market statistics, including tumor infiltrating lymphocytes industry global market size, regional shares, competitors with a tumor infiltrating lymphocytes market share, detailed tumor infiltrating lymphocytes market segments, market trends and opportunities, and any further data you may need to thrive in the tumor infiltrating lymphocytes industry. This tumor infiltrating lymphocytes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tumor infiltrating lymphocytes market size has grown rapidly in recent years. It will grow from $12.05 billion in 2025 to $13.75 billion in 2026 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to increasing cancer prevalence, advancements in immunotherapy research, rising awareness of personalized medicine, early success of adoptive cell therapies, collaborations between research institutes and biotech companies.

The tumor infiltrating lymphocytes market size is expected to see rapid growth in the next few years. It will grow to $23.25 billion in 2030 at a compound annual growth rate (CAGR) of 14.0%. The growth in the forecast period can be attributed to growing adoption of tumor infiltrating lymphocytes therapies, expansion of cGMP-compliant manufacturing facilities, integration of ai in cell therapy process optimization, rise in strategic partnerships between pharma and biotech, regulatory approvals for novel t-cell therapies. Major trends in the forecast period include personalized cell therapy development, ex vivo t-cell expansion techniques, immunotherapy combination approaches, tumor microenvironment modulation, advanced cell storage & cryopreservation.

The increasing number of cancer patients is expected to drive the growth of the tumor-infiltrating lymphocytes (TIL) market. Cancer occurs when some cells in the body grow uncontrollably and spread to other parts, leading to various health problems, including potentially fatal outcomes. Tumor-infiltrating lymphocytes are immune cells capable of detecting and destroying cancer cells. These lymphocytes are extracted from a patient's tumor, expanded in a laboratory, and then infused back into the patient to help the immune system fight cancer. For example, in August 2024, the Australian Institute of Health and Welfare projected that by 2034, Australia would have around 209,000 new cancer diagnoses, a significant increase from the 169,000 expected in 2024. This rise reflects both a growing population and increasing cancer rates. Cancer is also expected to account for about 3 out of every 10 deaths in the country in 2024. As a result, the growing number of cancer cases will drive the demand for TIL therapies.

Companies in the tumor-infiltrating lymphocyte market are increasingly adopting strategic partnerships to develop innovative treatments, including those involving gene editing. Strategic partnerships allow companies to leverage each other's strengths and resources to achieve mutual success. For instance, in February 2023, Moderna entered a partnership with Life Edit Therapeutics to accelerate the development of novel in vivo gene-editing therapies. This collaboration combines Moderna's mRNA technology with Life Edit's genome-editing platform to create more effective therapies for cancer and genetic disorders.

In May 2023, Phio Pharmaceuticals teamed up with AgonOx Inc. to advance TIL therapies for cancer treatment. This collaboration aims to combine Phio's engineered TIL technology with AgonOx's expertise in immuno-oncology, potentially improving treatment options for patients with solid tumors. AgonOx focuses on developing innovative therapies for cancer patients, further enhancing the potential of TIL-based treatments.

Major companies operating in the tumor infiltrating lymphocytes market are Novartis AG, Pfizer Inc., Precision BioScience Inc., TCR2 Therapeutics Inc., Merck KGaA, Autolus Therapeutics PLC., Eli Lilly and Company, Oxford Biomedica PLC., Unum Therapeutics Inc., Amgen Inc., Gilead Sciences Inc., Sorrento Therapeutics Inc., TILT Biotherapeutics Ltd., Iovance Biotherapeutics Inc., Adaptimmune Therapeutics plc, Atara Biotherapeutics Inc., BioNTech SE, CARsgen Therapeutics Ltd., Cellectis S.A., Celyad Oncology SA, CRISPR Therapeutics AG, Intellia Therapeutics Inc., MaxCyte Inc.

North America was the largest region in the tumor infiltrating lymphocytes market in 2025. The regions covered in the tumor infiltrating lymphocytes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the tumor infiltrating lymphocytes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tumor infiltrating lymphocytes market consists of sales of autologous TILs (tumor infiltrating lymphocytes), allogeneic TILs, and engineered TILs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tumor Infiltrating Lymphocytes Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses tumor infiltrating lymphocytes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tumor infiltrating lymphocytes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tumor infiltrating lymphocytes market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Anatomy: CD3; CD8; CD16; CD56; CD4; CD57; FOXP3
  • 2) By Component: T-Cells; Natural Killer Cells
  • 3) By Application: Melanoma; Cervical Cancer; Ovarian Cancer; Other Applications
  • 4) By End-User: Hospitals; Cancer Research Centers; Clinics
  • Companies Mentioned: Novartis AG; Pfizer Inc.; Precision BioScience Inc.; TCR2 Therapeutics Inc.; Merck KGaA; Autolus Therapeutics PLC.; Eli Lilly and Company; Oxford Biomedica PLC.; Unum Therapeutics Inc.; Amgen Inc.; Gilead Sciences Inc.; Sorrento Therapeutics Inc.; TILT Biotherapeutics Ltd.; Iovance Biotherapeutics Inc.; Adaptimmune Therapeutics plc; Atara Biotherapeutics Inc.; BioNTech SE; CARsgen Therapeutics Ltd.; Cellectis S.A.; Celyad Oncology SA; CRISPR Therapeutics AG; Intellia Therapeutics Inc.; MaxCyte Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Tumor Infiltrating Lymphocytes Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Tumor Infiltrating Lymphocytes Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Tumor Infiltrating Lymphocytes Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Tumor Infiltrating Lymphocytes Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Personalized Cell Therapy Development
    • 4.2.2 Ex Vivo T-Cell Expansion Techniques
    • 4.2.3 Immunotherapy Combination Approaches
    • 4.2.4 Tumor Microenvironment Modulation
    • 4.2.5 Advanced Cell Storage & Cryopreservation

5. Tumor Infiltrating Lymphocytes Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Cancer Research Centers
  • 5.3 Clinics
  • 5.4 Academic & Research Institutes
  • 5.5 Biotechnology Companies

6. Tumor Infiltrating Lymphocytes Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Tumor Infiltrating Lymphocytes Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Tumor Infiltrating Lymphocytes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Tumor Infiltrating Lymphocytes Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Tumor Infiltrating Lymphocytes Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Tumor Infiltrating Lymphocytes Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Tumor Infiltrating Lymphocytes Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Tumor Infiltrating Lymphocytes Market Segmentation

  • 9.1. Global Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • CD3, CD8, CD16, CD56, CD4, CD57, FOXP3
  • 9.2. Global Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • T-Cells, Natural Killer Cells
  • 9.3. Global Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Melanoma, Cervical Cancer, Ovarian Cancer, Other Applications
  • 9.4. Global Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals, Cancer Research Centers, Clinics, Academic & Research Institutes

10. Tumor Infiltrating Lymphocytes Market Regional And Country Analysis

  • 10.1. Global Tumor Infiltrating Lymphocytes Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Tumor Infiltrating Lymphocytes Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Tumor Infiltrating Lymphocytes Market

  • 11.1. Asia-Pacific Tumor Infiltrating Lymphocytes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Tumor Infiltrating Lymphocytes Market

  • 12.1. China Tumor Infiltrating Lymphocytes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Tumor Infiltrating Lymphocytes Market

  • 13.1. India Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Tumor Infiltrating Lymphocytes Market

  • 14.1. Japan Tumor Infiltrating Lymphocytes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Tumor Infiltrating Lymphocytes Market

  • 15.1. Australia Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Tumor Infiltrating Lymphocytes Market

  • 16.1. Indonesia Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Tumor Infiltrating Lymphocytes Market

  • 17.1. South Korea Tumor Infiltrating Lymphocytes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Tumor Infiltrating Lymphocytes Market

  • 18.1. Taiwan Tumor Infiltrating Lymphocytes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Tumor Infiltrating Lymphocytes Market

  • 19.1. South East Asia Tumor Infiltrating Lymphocytes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Tumor Infiltrating Lymphocytes Market

  • 20.1. Western Europe Tumor Infiltrating Lymphocytes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Tumor Infiltrating Lymphocytes Market

  • 21.1. UK Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Tumor Infiltrating Lymphocytes Market

  • 22.1. Germany Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Tumor Infiltrating Lymphocytes Market

  • 23.1. France Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Tumor Infiltrating Lymphocytes Market

  • 24.1. Italy Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Tumor Infiltrating Lymphocytes Market

  • 25.1. Spain Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Tumor Infiltrating Lymphocytes Market

  • 26.1. Eastern Europe Tumor Infiltrating Lymphocytes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Tumor Infiltrating Lymphocytes Market

  • 27.1. Russia Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Tumor Infiltrating Lymphocytes Market

  • 28.1. North America Tumor Infiltrating Lymphocytes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Tumor Infiltrating Lymphocytes Market

  • 29.1. USA Tumor Infiltrating Lymphocytes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Tumor Infiltrating Lymphocytes Market

  • 30.1. Canada Tumor Infiltrating Lymphocytes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Tumor Infiltrating Lymphocytes Market

  • 31.1. South America Tumor Infiltrating Lymphocytes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Tumor Infiltrating Lymphocytes Market

  • 32.1. Brazil Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Tumor Infiltrating Lymphocytes Market

  • 33.1. Middle East Tumor Infiltrating Lymphocytes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Tumor Infiltrating Lymphocytes Market

  • 34.1. Africa Tumor Infiltrating Lymphocytes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Segmentation By Component, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Tumor Infiltrating Lymphocytes Market Regulatory and Investment Landscape

36. Tumor Infiltrating Lymphocytes Market Competitive Landscape And Company Profiles

  • 36.1. Tumor Infiltrating Lymphocytes Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Tumor Infiltrating Lymphocytes Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Tumor Infiltrating Lymphocytes Market Company Profiles
    • 36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Precision BioScience Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. TCR2 Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis

37. Tumor Infiltrating Lymphocytes Market Other Major And Innovative Companies

  • Autolus Therapeutics PLC., Eli Lilly and Company, Oxford Biomedica PLC., Unum Therapeutics Inc., Amgen Inc., Gilead Sciences Inc., Sorrento Therapeutics Inc., TILT Biotherapeutics Ltd., Iovance Biotherapeutics Inc., Adaptimmune Therapeutics plc, Atara Biotherapeutics Inc., BioNTech SE, CARsgen Therapeutics Ltd., Cellectis S.A., Celyad Oncology SA

38. Global Tumor Infiltrating Lymphocytes Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Tumor Infiltrating Lymphocytes Market

40. Tumor Infiltrating Lymphocytes Market High Potential Countries, Segments and Strategies

  • 40.1 Tumor Infiltrating Lymphocytes Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Tumor Infiltrating Lymphocytes Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Tumor Infiltrating Lymphocytes Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제